The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary
Health. He is a member of the Delta Dental Foundation Board and chairs the board of directors for LiveWell, Colorado. Nationally, Dr. Calonge is the chair of the United States Preventive Services Task Force and a member of the Centers for Disease Control and Prevention’s (CDC’s) Task Force on Community Preventive Services. He is the chair of the CDC’s Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Workgroup and is a member of the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children in the Maternal and Child Health Bureau in the Health Resources and Services Administration. Dr. Calonge received his B.A. in chemistry from the Colorado College, his M.D. from the University of Colorado and his M.P.H. from the University of Washington; he is board certified in both family medicine and preventive medicine. Prior to coming to the trust, Dr. Calonge was the chief medical officer of the Colorado Department of Public Health and Environment.
Aled Edwards, Ph.D., is Banbury Professor of Medical Research at the University of Toronto, visiting professor of chemical biology at the University of Oxford, and chief executive of the Structural Genomics Consortium (SGC), an Anglo–Canadian–Swedish public-private partnership created to increase substantially the number of protein structures of relevance to human health available in the public domain, without restriction on use. Funded by industry, governments, and charitable foundations, the SGC accounts for more than a quarter of the world’s output of human protein structures and more than 75 percent of the world’s output of proteins from the parasites that cause malaria, toxoplasmosis, and cryptosporidiosis. Dr. Edwards believes that the discovery of new medicines would be most efficiently accomplished by performing many aspects of drug discovery research, from discovery to clinical proof of concept, within pre-competitive research consortia, and by de-emphasizing the perceived value of patents. Dr. Edwards was scientific consultant for the Canadian dramatic TV series, ReGenesis, and has founded a number biotechnology companies.
Robert S. Epstein, M.D., M.S., is chief medical officer and president, Medco Research Institute, Medco Health Solutions, Inc. Dr. Epstein joined Medco in 1995 and has served as chief medical officer since 1997. In this capacity, he is responsible for formulary development, clinical guidelines, drug information services, accreditation oversight, and personalized medicine services. He is also responsible for analysis and reporting for Medco’s clients. In 2009, Dr. Epstein was named president of the Medco Research Institute, where he oversees Medco’s peer-reviewed research initiatives and collaborations in the areas of personalized medicine, comparative effectiveness, and chronic conditions. Dr. Epstein was trained as an epidemiologist and worked in public health and academia